scholarly journals MP32-04 RENAL CELL CARCINOMA IN THE NATIVE KIDNEY IN DIALYSIS AND KIDNEY TRANSPLANT RECIPIENTS. COMPARISON OF PATHOLOGICAL FEATURES AND ACKD INFLUENCE.

2016 ◽  
Vol 195 (4S) ◽  
Author(s):  
Kleiton Yamaçake ◽  
William Nahas ◽  
Ioannis Antonopoulos ◽  
Hideki Kanashiro ◽  
Raphael Kato ◽  
...  
2020 ◽  
Vol 51 (10) ◽  
pp. 777-785
Author(s):  
Rushad Machhi ◽  
Didier A. Mandelbrot ◽  
Talal Al-Qaoud ◽  
Brad C. Astor ◽  
Sandesh Parajuli

<b><i>Background:</i></b> The incidence of renal cell carcinoma (RCC) is higher in kidney transplant recipients (KTRs) compared to the general population. However, the risk factors and outcomes based on the diagnosis of RCC after kidney transplantation are limited. <b><i>Methods:</i></b> We analyzed risk factors for the development of RCC in KTRs transplanted at our institution between 1994 and 2016. We compared the incidence of graft failure and mortality in KTRs with RCC to matched controls using 5:1 event density sampling. Identifying the risk factors of RCC and patient and graft survival were outcomes of interest. <b><i>Results:</i></b> There were 4,178 KTRs performed at our institution during the study period, and 51 patients were diagnosed with RCC. Recipients were followed until graft failure or death. We did not identify commonly looked at baseline characteristics associated with the risk of RCC. Comparing KTRs with RCC to matched controls, RCC patients were younger (47.5 vs. 49.6 years, <i>p</i> &#x3c; 0.01), received basiliximab induction more commonly (<i>p</i> = 0.01), had hypertension and glomerulonephritis as causes of end-stage renal disease (<i>p</i> = 0.01), and were more likely to be smokers (<i>p</i> &#x3c; 0.01). RCC was significantly associated with death-censored graft failure (adjusted hazard ratio [HR]: 1.76; 95% CI: 1.02–3.03; <i>p</i> = 0.04) but not patient death (adjusted HR: 0.95; 95% CI: 0.50–1.83; <i>p</i> = 0.89). <b><i>Conclusion:</i></b> In our experience, RCC had a detrimental impact on graft survival among KTRs, highlighting the potential benefit of early diagnosis and optimal immunosuppression management in optimizing graft survival.


2016 ◽  
Vol 16 (12) ◽  
pp. 3479-3489 ◽  
Author(s):  
S. Karami ◽  
E. L. Yanik ◽  
L. E. Moore ◽  
R. M. Pfeiffer ◽  
G. Copeland ◽  
...  

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e16066-e16066
Author(s):  
Sabeeh-Ur-Rehman Butt ◽  
Barbara Chow ◽  
Sapna Shah ◽  
Iain MacDougall ◽  
Catriona Shaw ◽  
...  

e16066 Background: The increased incidence of cancer after renal transplantation is well recognised. Differences in cancer risk depend on the type of cancer but overall the incidence of solid cancer in kidney transplant recipient is at least twofold. Long term immunosuppression, oncogenic viruses and changes in immune surveillance are contributing factors. The incidence of renal cell carcinoma (RCC) is approximately six-fold greater than in the general population. Screening for RCC in the post-transplantation setting is not routine. Methods: Retrospective case series of kidney transplant recipients who underwent transplantation between 1987 and 2018 at Guy’s Hospital (London, UK). Collected data on patients who developed RCC post-transplant included: baseline demographics, renal disease, transplant survival, tumour characteristics, cancer treatment and survival. Results: 2968 patients underwent kidney transplantation between 1987 and 2018 at our Centre. 52 patients (1.8%) developed RCC. 40 (74%) were male with a median age of 51 years. 37% (71%) were white and 12 (23%) were black. The causes of end stage kidney disease included IgA nephropathy, hypertension and polycystic kidney disease. Median time to RCC diagnosis after transplant was 9 years (range 0-27). 86% of patients presented with stage 1/2 tumours, with the majority (72%) occurring in native kidneys. Most underwent radical nephrectomy although 5 patients were managed with radiofrequency-ablation (RFA) or surveillance (donor kidneys). Of 6 patients with metastatic disease, 5 received pazopanib and 1 everolimus. 4 patients continued systemic therapy for over 3 months and all derived clinical benefit with a median drug exposure of 19 months .15 patients required further kidney transplant or dialysis. Overall only 2 patients died from RCC. Conclusions: This retrospective study is the largest single-centre UK study to our knowledge. Kidney transplant recipients experience a marked increased risk of developing RCC. Most diagnosed RCCs are small and disease-specific mortality is low. With a third of tumours arising in donor organs, questions around optimum loco-regional approach and screening of high-risk population remain unanswered.


2012 ◽  
Vol 53 (4) ◽  
pp. 229 ◽  
Author(s):  
Hyung Ho Lee ◽  
Kyung Hwa Choi ◽  
Seung Choul Yang ◽  
Woong Kyu Han

Sign in / Sign up

Export Citation Format

Share Document